Ezio Bonvini
Overview
Explore the profile of Ezio Bonvini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
2903
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huang R, Spliedt M, Kaufman T, Gorlatov S, Barat B, Shah K, et al.
Antibodies (Basel)
. 2025 Jan;
14(1.
PMID: 39846615
Bispecific antibodies represent a promising class of biologics for cancer treatment. However, their dual specificity and complex structure pose challenges in the engineering process, often resulting in molecules with good...
2.
Brignole C, Calarco E, Bensa V, Giusto E, Perri P, Ciampi E, et al.
J Immunother Cancer
. 2023 Sep;
11(9).
PMID: 37775116
Introduction: B7-H3 is a potential target for pediatric cancers, including neuroblastoma (NB). Vobramitamab duocarmazine (also referred to as MGC018 and herein referred to as vobra duo) is an investigational duocarmycin-based...
3.
Rimando J, Chendamarai E, Rettig M, Jayasinghe R, Christopher M, Ritchey J, et al.
Blood
. 2022 Dec;
141(14):1718-1723.
PMID: 36563336
Acute myeloid leukemia (AML) relapse is one of the most common and significant adverse events following allogeneic hematopoietic cell transplantation (HCT). Downregulation of major histocompatibility class II (MHC-II) surface expression...
4.
Scribner J, Hicks S, Sinkevicius K, Yoder N, Diedrich G, Brown J, et al.
Mol Cancer Ther
. 2022 May;
21(7):1047-1059.
PMID: 35511740
ADAM metallopeptidase domain 9 (ADAM9) is a member of the ADAM family of multifunctional, multidomain type 1 transmembrane proteins. ADAM9 is overexpressed in many cancers, including non-small cell lung, pancreatic,...
5.
Aggarwal C, Prawira A, Antonia S, Rahma O, Tolcher A, Cohen R, et al.
J Immunother Cancer
. 2022 Apr;
10(4).
PMID: 35414591
Background: Availability of checkpoint inhibitors has created a paradigm shift in the management of patients with solid tumors. Despite this, most patients do not respond to immunotherapy, and there is...
6.
Barwe S, Kisielewski A, Bonvini E, Muth J, Davidson-Moncada J, Kolb E, et al.
J Clin Med
. 2022 Mar;
11(5).
PMID: 35268423
Children with acute myeloid leukemia (AML) have a poor prognosis despite the intensification of chemotherapy. Future efforts to improve outcomes should focus on more precise targeting of leukemia cells. CD123,...
7.
Crespo J, Koh Y, Hu N, Moore P, Bonvini E, Glasebrook A, et al.
PLoS One
. 2021 Feb;
16(2):e0245917.
PMID: 33596227
Pre-clinical murine models are critical for translating drug candidates from the bench to the bedside. There is interest in better understanding how anti-human CD3 therapy works based on recent longitudinal...
8.
Rugo H, Im S, Cardoso F, Cortes J, Curigliano G, Musolino A, et al.
JAMA Oncol
. 2021 Jan;
7(4):573-584.
PMID: 33480963
Importance: ERRB2 (formerly HER2)-positive advanced breast cancer (ABC) remains typically incurable with optimal treatment undefined in later lines of therapy. The chimeric antibody margetuximab shares ERBB2 specificity with trastuzumab but...
9.
Berezhnoy A, Sumrow B, Stahl K, Shah K, Liu D, Li J, et al.
Cell Rep Med
. 2020 Dec;
1(9):100163.
PMID: 33377134
Combination immunotherapy with antibodies directed against PD-1 and CTLA-4 shows improved clinical benefit across cancer indications compared to single agents, albeit with increased toxicity. Leveraging the observation that PD-1 and...
10.
Scribner J, Brown J, Son T, Chiechi M, Li P, Sharma S, et al.
Mol Cancer Ther
. 2020 Sep;
19(11):2235-2244.
PMID: 32967924
B7-H3, also referred to as CD276, is a member of the B7 family of immune regulatory proteins. B7-H3 is overexpressed on many solid cancers, including prostate cancer, renal cell carcinoma,...